Neuronata-R Keeps Korea ALS Conditional Nod
Neuronata-R MFDS ALS South Korea approval status remains in place after a May 2026 label update, CorestemChemon said on July 19, 2026. The autologous mesenchymal stem-cell therapy stays on the market while manufacturing restarts and a U.S. BLA path is prepared.
Contents9 sections
Key Takeaways
- MFDS approved a May 2026 license modification keeping Neuronata-R available for ALS in Korea.
- ALSummit missed the full-population primary CAFS endpoint but showed subgroup benefit in slow progressors, per the company.
- Label now reflects Phase 3 data; conditional approval dating to 2014 continues.
- Full-scale production restart is targeted for early next year; FDA Type C / BLA planning continues.
Neuronata-R Korea update at a glance
| Field | Detail |
|---|---|
| Product | Neuronata-R (lenzumestrocel) |
| Company | CorestemChemon Inc. |
| Modality | Autologous bone marrow–derived MSCs, intrathecal |
| Regulator | Korea MFDS |
| Action | License modification / continued conditional use (May 2026; announced July 19, 2026) |
| Confirmatory trial | ALSummit Phase 3 (NCT04745299) |
| Prior status | Conditional approval since 2014; >400 patients treated in Korea (company) |
What did the company announce?
CorestemChemon said MFDS reviewed the completed Phase 3 package and kept Neuronata-R authorized with an updated label. That decision preserves domestic access while the firm rebuilds supply and expands U.S. research ties through the Piedmont Triad Regenerative Medicine Engine.
Source: CorestemChemon's July 19 PR Newswire release. Trial identification is on ClinicalTrials.gov for ALSummit (NCT04745299).
How should readers interpret the Phase 3 miss?
A full-population primary miss with subgroup success is a classic rare-disease evidence tension. MFDS chose continued availability with label transparency rather than withdrawal. Clinicians should read the updated Korean label for who is most likely to benefit and should not extrapolate subgroup CAFS gains to all ALS phenotypes.
Neuronata-R holds orphan designations from the U.S. FDA (2018) and EMA (2019); orphan-framework context is on FDA's orphan product designation page.
What is the proposed mechanism?
- Autologous MSCs expanded from patient bone marrow
- Intrathecal delivery rather than motor-neuron replacement
- Proposed secreted anti-inflammatory (TGF-β1, IL-4, IL-10) and neuroprotective (VEGF, BDNF, IGF) factors
These mechanistic claims remain hypothesis-level relative to confirmatory efficacy. Manufacturing restart timing will determine when Korean patients and, later, inbound international patients can again receive courses.
What remains uncertain?
Exact label language on slow-progressor selection, reimbursement continuity during the manufacturing gap, and whether FDA will accept a subgroup-driven BLA strategy after Type C feedback are all open. Cross-border medical travel for cell therapy raises separate legal and quality-control issues outside MFDS's Korea authorization.
Related NovaPharma coverage
- Orzeyful: NMPA Clears First OX2R Agonist for NT1
- NMPA Approves Ciprocopan for PNH in China
- LEQEMBI LEADER Study: Real-World Data at AAIC 2026
Frequently Asked Questions
What did MFDS decide on Neuronata-R?
CorestemChemon said South Korea's Ministry of Food and Drug Safety approved a product license modification in May 2026 that keeps Neuronata-R (lenzumestrocel) available for ALS, updating the label to reflect completed Phase 3 ALSummit data. The therapy was first conditionally approved in Korea in 2014.
What did the ALSummit Phase 3 trial show?
In ALSummit (NCT04745299), Neuronata-R did not reach statistical significance on the primary Combined Assessment of Function and Survival endpoint in the full study population. In a slow-progressor subgroup, the company said the therapy met CAFS and ALSFRS-R endpoints and lowered neurofilament light chain, with consistent slow vital capacity trends.
What are CorestemChemon's next steps?
The company said it is working to resume full-scale manufacturing early next year, may then treat international patients traveling to Korea, and is pursuing an FDA Type C meeting with a goal of filing a U.S. Biologics License Application the following year. Neuronata-R holds FDA and EMA orphan designations.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Neuronata-R.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives — Patient and care partner perspectives inform FDA’s thinking on approved gene therapy safety and long…